rAAV-CMV
Recombinant adeno-associated viruses (rAAVs) using the CMV promoter are among the most widely utilized vectors for gene delivery. The CMV promoter is derived from the cytomegalovirus immediate-early enhancer/promoter, known for driving strong and constitutive expression of transgenes in a variety of cell types.
Features of rAAV-CMV
- Strong and Ubiquitous Expression:
- The CMV promoter ensures high-level transgene expression in both dividing and non-dividing cells.
- Expression is not cell-type-specific, making it ideal for generalized applications.
- Cross-Species Compatibility:
- Functional across many species, including humans, rodents, and non-human primates.
- Rapid Onset:
- Transgene expression occurs quickly after delivery, making it suitable for acute studies.
Applications of rAAV-CMV
- Gene Therapy:
- Delivery of therapeutic genes to correct genetic deficiencies or modulate disease pathways (e.g., factor VIII for hemophilia or neurotrophic factors for neurodegeneration).
- Molecular and Cellular Research:
- Overexpression of proteins to study their function in vitro or in vivo.
- Delivery of fluorescent reporters (e.g., GFP, RFP) for imaging and tracking cells.
- CRISPR/Cas9 and Genome Editing:
- Delivery of Cas9 or other gene-editing components to target and modify genes of interest.
- Protein Production:
- Expression of recombinant proteins for preclinical studies or in biomanufacturing.
- Animal Models:
- Generation of disease models by overexpressing or knocking down genes involved in pathogenesis.
rAAV-CMV is a versatile and widely used system for gene delivery, particularly suited for applications requiring robust and widespread transgene expression. While it lacks cell-type specificity, its broad utility and strong expression make it a valuable tool in both research and therapeutic settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|